Pemetrexed-RZ Pemetrexed Disodium 500 mg injection vial

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

pemetrexed disodium, Quantity: 551.4 mg (Equivalent: pemetrexed, Qty 500 mg)

Commercializzato da:

Dr Reddys Laboratories Australia Pty Ltd

INN (Nome Internazionale):

pemetrexed disodium

Forma farmaceutica:

Injection, powder for

Composizione:

Excipient Ingredients: hydrochloric acid; water for injections; mannitol; sodium hydroxide

Via di somministrazione:

Intravenous

Confezione:

1 X 500 mg/vial

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Malignant Pleural Mesothelioma:,Pemetrexed-RZ, in combination with cisplatin, is indicated for the treatment of patients with malignant,pleural mesothelioma.,Non-Small Cell lung Cancer:,Pemetrexed-RZ in combination with cisplatin is indicated for initial treatment of patients with locally,advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,Pemetrexed-RZ as monotherapy is indicated for the treatment of patients with locally advanced or,metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior,platinum-based chemotherapy.

Dettagli prodotto:

Visual Identification: Pemetrexed disodium for injection 500 mg/vial is a white to either light-yellow or green-yellow lyophilised powder packed in 50 mL glass vial with 20 mm rubber stopper and sealed with 20 mm aluminium flip-off seal; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2014-05-19